In addition to melanoma, Moderna and Merck are conducting trials with personalized injections to fight types of bladder, kidney, and lung cancers.
A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage testing results.
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and ...
The updated 2024-2025 mRNA COVID vaccine from Moderna does not appear to carry the same risk for myocarditis in young adults that the first mRNA COVID vaccines did, suggested research presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results